Author

Christopher I Amos

Director of Clinical and Translational Research, Baylor College of Medicine - Cited by 75,410 - Statistical Genetics - Genetic Epidemiology - Genomics

Biography

Christopher Ian Amos is an American genetic epidemiologist and the director of the Institute for Clinical and Translational Research at Baylor College of Medicine, where he is also the associate director for quantitative science at the Dan L Duncan Comprehensive Cancer Center
Title
Cited by
Year
Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program
HA Robbins, K Alcala, EK Moez, F Guida, S Thomas, H Zahed, ...Annals of epidemiology 77, 1-12, 2023202
11
2023
Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems
A Li, J La, SB May, D Guffey, WL da Costa, CI Amos, R Bandyo, EM Milner, ...Journal of Clinical Oncology 41 (16), 2926-293, 2023202
8
2023
Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation
GM Leyden, MP Greenwood, V Gaborieau, Y Han, CI Amos, P Brennan, ...British Journal of Cancer 12 (4), 61-625, 2023202
8
2023
Inflammatory Biomarkers Differ among Hospitalized Veterans Infected with Alpha, Delta, and Omicron SARS-CoV-2 Variants
C Park, S Tavakoli-Tabasi, A Sharafkhaneh, BJ Seligman, B Hicken, ...International Journal of Environmental Research and Public Health 20 (4), 2987, 20233202
3
2023
Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics
KM Walsh, C Neff, ML Bondy, C Kruchko, JT Huse, CI Amos, ...Neuro-oncology 25 (2), 98-406, 20220
3
2023
Clonal hematopoiesis and risk of incident lung cancer
R Tian, B Wiley, J Liu, X Zong, B Truong, S Zhao, MM Uddin, A Niroula, ...Journal of Clinical Oncology 41 (7), 143-1433, 030
2
2023
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
HS Lee, HJ Jang, M Ramineni, DY Wang, D Ramos, JM Choi, T Splawn, ...Clinical Cancer Research 9 (3), 548-559, 030
2
2023
Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment
LS Chen, TB Baker, A Ramsey, CI Amos, LJ BierutAddiction Neuroscience 7, 00083, 2023202
1
2023
The blood proteome of imminent lung cancer diagnosis.
D Albanes, K Alcala, N Alcala, CI Amos, AA Arslan, JK Bassett, P Brennan, ...Nature Communications 4 (), 2023202
1
2023
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population
J Shi, K Shiraishi, J Choi, K Matsuo, TY Chen, J Dai, RJ Hung, K Chen, ...Nature communications 4 (), 3043, 2023202
1
2023
The genomic landscape of familial glioma
DJ Choi, G Armstrong, B Lozzi, P Vijayaraghavan, SE Plon, TC Wong, ...Science Advances 9 (7), eade2675, 2023202
1
2023
Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes
N van Zandwijk, CI Amos, OD Røe, G Reid, S KlebeJTO Clinical and Research Reports 4 (4), 2023202
1
2023
Why does the X chromosome lag behind autosomes in GWAS findings?
IP Gorlov, CI AmosPLoS Genetics 9 (2), e00472, 2023202
1
2023
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis
Y Han, J Byun, C Zhu, R Sun, JY Roh, HJ Cordell, HS Lee, VR Shaw, ...Nature communications 4 (), 069, 2023202
1
2023

Referred From: https://scholar.google.co.in/citations?user=nziLHh4AAAAJ&hl=en

Cited by
Citations 75410
h-index 133
i10-index 656
Recommended Journals
Open Access Journals